Accelerate Tox Material Delivery and Stay on Track for IND Submission

As development timelines tighten, generating toxicology (tox) data quickly has become a critical milestone on the path to IND submission. Delays in tox material supply can slow investment decisions, extend development timelines, and postpone first-in-human studies.

Lonza’s rapid tox approach is designed to help drug developers accelerate tox material generation while maintaining flexibility across molecule types and development strategies.

Key Capabilities

• Early use of pool material to initiate tox and formulation studies
• Parallel process, analytical, and formulation development
• Platform-based purification and formulation strategies
• Flexible CMC pathways tailored to molecule complexity

Why It Matters

Faster access to tox data allows sponsors to reduce risk earlier, maintain development momentum, and move confidently toward IND submission and first-in-human studies.

In a competitive IND landscape, speed and flexibility are essential. Lonza’s rapid tox approach helps drug developers secure critical tox data sooner and keep IND timelines on track.